Genomics and Burden of Disease in the Netherlands: An Estimate of Genetic Contribution to DALYs
Abstract
Background: Genomics is an increasingly recognised but poorly quantified contributor to disease burden. Existing frameworks for burden of disease — including the Dutch Public Health Foresight Study — cover 106 diseases and 120 determinant groups, but genetic factors have not yet been systematically integrated. This study presents first estimates of the genomic contribution to disability-adjusted life years (DALYs) in the Netherlands.
Methods: For a selection of the most relevant diseases, the proportion of disease burden attributable to genomic factors was estimated using three primary sources: VZinfo.nl, Erfelijkheid.nl, and Zicht op Zeldzaam. Where possible, minimum and maximum attributable fractions were derived and combined with current DALY estimates from Dutch burden of disease data. Scientific literature requiring targeted searches was not included in this version. No distinction was made between morbidity and mortality contributions.
Results: Genomic attribution varied substantially across disease groups. The highest attributable fractions were found for breast cancer (∼25%), diabetes (10–20%), anxiety and stress disorders (∼10%), and neck and back complaints (∼10%). Expressed in absolute DALYs, anxiety disorders, breast cancer, neck and back complaints, and diabetes showed the largest genomic contributions. Across all selected diseases, total genomically attributable DALYs range from approximately 100,000 to 132,000. As a proportion of total burden, this represents 3.1–4.0% of DALYs for selected diseases and 1.9–2.5% of all Dutch DALYs.
Discussion: This is a first and exploratory step toward integrating genomics into burden of disease frameworks. Validation is challenging given the limited availability of comparable approaches. Genetic factors also modify risk factor pathways, including addiction and overweight, suggesting that current estimates are conservative. Further methodological development is needed.
Key messages: • Genomic factors account for 1.9–2.5% of total disease burden (DALYs) in the Netherlands, with highest impact in breast cancer, diabetes, and anxiety disorders.
• This study is a first step in systematically integrating genomics into public health burden frameworks, highlighting the need for further research and validation.
Related
- Points to consider for the reporting of variants of uncertain significance in germline genetic and genomic testing: A statement of the American College of Medical Genetics and Genomics (ACMG)
- Comparative Genomics Reveals Genetic Factors Associated with Intraspecific Pigmentation Differences in Cassava
- Refining the genetic architecture of myocardial infarction through integrative post-genome-wide association study functional genomics analysis
- Elucidating the evolution of litchi: insights into the population genomics of ancient trees on origin, dispersal, and adaptive genetic basis
- Population genomics of Candida albicans reveals genetic footprints that allow the prediction of antifungal resistance
BibTeX
@article{hilderink2026genomics,
title = {{Genomics and Burden of Disease in the Netherlands: An Estimate of Genetic Contribution to DALYs}},
author = {HBM Hilderink and A De Bruijn and M Van der Noord and S Onstwedder and S Heil},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.581},
url = {https://doi.org/10.1093/eurpub/ckag169.581},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Genomics and Burden of Disease in the Netherlands: An Estimate of Genetic Contribution to DALYs
AU - HBM Hilderink
AU - A De Bruijn
AU - M Van der Noord
AU - S Onstwedder
AU - S Heil
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.581
UR - https://doi.org/10.1093/eurpub/ckag169.581
AB - Background: Genomics is an increasingly recognised but poorly quantified contributor to disease burden. Existing frameworks for burden of disease — including the Dutch Public Health Foresight Study — cover 106 diseases and 120 determinant groups, but genetic factors have not yet been systematically integrated. This study presents first estimates of the genomic contribution to disability-adjusted life years (DALYs) in the Netherlands. Methods: For a selection of the most relevant diseases, the proportion of disease burden attributable to genomic factors was estimated using three primary sources: VZinfo.nl, Erfelijkheid.nl, and Zicht op Zeldzaam. Where possible, minimum and maximum attributable fractions were derived and combined with current DALY estimates from Dutch burden of disease data. Scientific literature requiring targeted searches was not included in this version. No distinction was made between morbidity and mortality contributions. Results: Genomic attribution varied substantially across disease groups. The highest attributable fractions were found for breast cancer (∼25%), diabetes (10–20%), anxiety and stress disorders (∼10%), and neck and back complaints (∼10%). Expressed in absolute DALYs, anxiety disorders, breast cancer, neck and back complaints, and diabetes showed the largest genomic contributions. Across all selected diseases, total genomically attributable DALYs range from approximately 100,000 to 132,000. As a proportion of total burden, this represents 3.1–4.0% of DALYs for selected diseases and 1.9–2.5% of all Dutch DALYs. Discussion: This is a first and exploratory step toward integrating genomics into burden of disease frameworks. Validation is challenging given the limited availability of comparable approaches. Genetic factors also modify risk factor pathways, including addiction and overweight, suggesting that current estimates are conservative. Further methodological development is needed. Key messages: • Genomic factors account for 1.9–2.5% of total disease burden (DALYs) in the Netherlands, with highest impact in breast cancer, diabetes, and anxiety disorders. • This study is a first step in systematically integrating genomics into public health burden frameworks, highlighting the need for further research and validation.
SN - 1101-1262
SN - 1464-360X
ER -